Medifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity L5461, A174976.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Hydrocodone | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Magnesium sulfate | The therapeutic efficacy of Medifoxamine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Medifoxamine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Mirtazapine | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Orphenadrine | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Pramipexole | Medifoxamine may increase the sedative activities of Pramipexole. |
| Ropinirole | Medifoxamine may increase the sedative activities of Ropinirole. |
| Rotigotine | Medifoxamine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Medifoxamine. |
| Sodium oxybate | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Thalidomide | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Medifoxamine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Medifoxamine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Medifoxamine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Medifoxamine is combined with (S)-Warfarin. |
| Ethanol | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Alaproclate. |
| Zopiclone | The risk or severity of adverse effects can be increased when Medifoxamine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Medifoxamine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Medifoxamine. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Medifoxamine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Medifoxamine. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Medifoxamine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Medifoxamine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Medifoxamine. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Medifoxamine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Medifoxamine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Medifoxamine. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Medifoxamine. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Medifoxamine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Medifoxamine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Medifoxamine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Medifoxamine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Medifoxamine. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Medifoxamine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Medifoxamine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Medifoxamine. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Medifoxamine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Medifoxamine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Medifoxamine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Medifoxamine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Medifoxamine. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Medifoxamine. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Medifoxamine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Medifoxamine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Medifoxamine. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Medifoxamine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Medifoxamine. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Medifoxamine. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Medifoxamine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Medifoxamine. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Medifoxamine. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Medifoxamine. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Medifoxamine. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Medifoxamine. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Medifoxamine. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Medifoxamine. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Medifoxamine. |